Macrophage Endocytosis of Superparamagnetic Iron Oxide Nanoparticles: Mechanisms and Comparison of Ferumoxides and Ferumoxtran-10

Investigative Radiology

Volumn 39, Issue 1, 2004, Pages 56-63

  Raynal, Isabelle ^a   Prigent, Philippe ^a   Peyramaure, Sophie ^a   Najid, Abderrahim ^a   Rebuzzi, Cécile ^a   Corot, Claire ^a  

^a Laboratoire Guerbet   (France)

Author keywords

Contrast agents; Endocytosis; Iron oxide; Macrophages; Scavenger receptors

Indexed keywords

CONTRAST MEDIUM; FERRIC FERROCYANIDE; FERUMOXTRAN 10; FUCOIDIN; NANOPARTICLE; POLYINOSINIC ACID; SCAVENGER RECEPTOR; SUPERPARAMAGNETIC IRON OXIDE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; ATOMIC EMISSION SPECTROMETRY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG UPTAKE; ENDOCYTOSIS; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNALIZATION; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; PERITONEUM MACROPHAGE; PRIORITY JOURNAL;

EID: 0348050037     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rli.0000101027.57021.28     Document Type: Article

References (36)

1. Stark DD, Weissleder R, Elizondo G, et al. Superparamagnetic iron oxide: clinical applications as a contrast agent for MR imaging of the liver. Radiology. 1988;168:297-301.
2. Weissleder R, Hahn PF, Stark DD, et al. Superparamagnetic iron oxide: enhanced detection of splenic tumors with MR imaging. Radiology. 1988;169:399-403.
3. Benderbous S, Corot C, Jacobs P, et al. Superparamagnetic agents: physicochemical characteristics and preclinical imaging evaluation. Acad Radiol. 1996;3:S292-S294.
4. Marchal G, Van Hecke P, Demaerel P, et al. Detection of liver metastasis with superparamagnetic iron oxide in 15 patients: results of MR imaging at 1.5 T. AJR. 1989;152:771-775.
5. Ros PR, Freeny PC, Harms SE, et al. Efficacy of superparamagnetic iron oxide as an adjunct to MR imaging of the liver: results of a multicenter trial [Abstract]. Radiology 1993;189(P):202.
6. Denys A, Arrivé L, Servois V, et al. Hepatic tumors: detection and characterization at 1 T MR imaging enhanced with AM1-25. Radiology. 1994;193:665-669.
7. Jung G, Krahe T, Kugel H, et al. Detection of focal hepatic lesions: effects of superparamagnetic iron oxide (AM1-25) on magnetic resonance imaging of the liver using T2-weighted fast spin-echo sequences and gradient-and-spin-echo sequences at 1.0 Tesla. Invest Radiol. 1998;33:61-67.
8. Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med. 2003;348:2491-2499.
9. Kotyk A. Transport of macromolecules. In: Kotyk A, Janacek K, Koryta J, eds. Biophysical chemistry of membrane functions. Chichester, UK: John Wiley & Sons Ltd.; 1988:221-233.
10. Schulze E, Ferrucci JT, Poss K, et al. Cellular uptake and trafficking of a prototypical magnetic iron oxide label in vitro. Invest Radiol. 1995;30:604-610.
11. Krieger M, Herz J. Structures and functions of multiligand lipoprotein receptors: macrophage scavenger receptor and LDL receptor-related protein. Annu Rev Biochem. 1994;63:601-637.
12. Pratten MK, Lloyd JB. Pinocytosis and phagocytosis: the effect of size of a particulate substrate on its mode of capture by rat peritoneal macrophages cultured in vivo. Biochim Biophys Acta. 1986;881:307-313.
13. Krieger M. The other side of scavenger receptors: pattern recognition for host defense. Curr Opin Lipidol. 1997;8:275-280.
14. Platt N, Gordon S. Scavenger receptors: diverse activities and promiscuous binding of polyanionic ligands. Chem Biol. 1998;5:R193-R203.
15. Dhaliwal BS, Steinbrecher UP. Scavenger receptors and oxidized low density lipoproteins. Clin Chim Acta. 1999;286:191-205.
16. de Winther MP, van Dijk KW, Havekes LM, et al. Macrophage scavenger receptor class A: a multifunctional receptor in atherosclerosis. Arterioscler Thromb Vasc Biol. 2000;20:290-297.
17. Yamada Y, Doi T, Hamakubo T, et al. Scavenger receptor family proteins: roles for atherosclerosis, host defense and disorders of the central nervous system. Cell Mol Life Sci. 1998;54:628-640.
18. Shirai H, Murakami T, Yamada Y, et al. Structure and function of type I and II macrophage scavenger receptors. Mech Ageing Dev. 1999;111:107-121.
19. Tsuchiya S, Yamabe M, Yamaguchi Y, et al. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer 1980;26:171-176.
20. Koval M, Preiter K, Adles C, et al. Size of IgG-opsonized particles determines macrophage response during internalisation. Exp Cell Res. 1998;242:265-273.
21. Weissleder R, Cheng HC, Bogdanova A, et al. Magnetically labelled cells can be detected by MR Imaging. J Magn Reson Imaging. 1997;7:258-263.
22. Ross JA, Auger MJ. The biology of the macrophages. In: Burke B, Lewis CE, eds. The macrophage. 2nd ed. New York, NY: Oxford University Press Inc.; 2002:1-72.
23. Shanbhag AS, Jacobs JJ, Black J, et al. Macrophage/particle interactions: effect of size, composition and surface area. J Biomed Mater Res. 1994;28:81-90.
24. Acton S, Scherer P, Lodish H, et al. Expression cloning of SR-B I, a CD36-related class B scavenger receptor. J Biol Chem. 1994;269:21003-21009.
25. Lysko PG, Weinstock J, Webb CL, et al. Identification of a small-molecule, nonpeptide macrophage scavenger receptor antagonist. J Pharmacol Exp Ther. 1999;289:1277-1285.
26. McLachlan SJ, Morris MR, Lucas MA, et al. Phase I clinical evaluation of a new iron oxide MR Contrast agent. J Magn Reson Imaging. 1994;4:301-307.
27. Mehvar R. Dextrans for targeted and sustained delivery of therapeutic and imaging agents. J Control Release. 2001;69:1-25.
28. Bonnemain B. Superparamagnetic agents in magnetic resonance imaging: physicochemical characteristics and clinical applications: a review. J Drug Target. 1998;6:167-174.
29. Bremer C, Allkemper T, Baermig J, et al. RES-specific imaging of the liver and spleen with iron oxide particles designed for blood pool MR angiography. J Magn Reson Imaging. 1999;10:461-467.
30. Dousset V, Doche B, Petry KG, et al. Correlation between clinical status and macrophage activity imaging in rats central nervous system. Acad Radiol. 2002;9(suppl 1):156-159.
31. Taupitz M, Schmidtz SA, Beyersdorff D, et al. Magnetic resonance imaging of atherosclerotic plaques using superparamagnetic iron oxide particles. J Magn Reson Imaging. 2001;14:355-361.
32. Ruehm S. G, Corot C, Vogt P, et al. Magnetic resonance Imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits. Circulation. 2001;103:415-422.
33. Kooi ME, Cappendijk VC, Cleutjens KBJM, et al. Accumulation of ultrasmall superparamagnetic particles of iron oxides in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation. 2003;107:2453-2458.
34. Hauger O, Delalande C, Trillaud H, et al. MR imaging of intrarenal macrophage infiltration in an experimental model of nephritic syndrome. Magn Reson Med. 1999;41:156-162.
35. Hauger O, Delalande C, Trillaud H, et al. Nephrotoxic nephritis and obstructive nephropathy: evaluation with MR imaging enhanced with ultrasmall superparamagnetic iron oxide-preliminary findings in a rat model. Radiology. 2000;217:819-826.
36. Jung CW, Jacobs P. Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: Ferumoxides, Ferumoxtran, Ferumoxsil. Magn Reson Imaging. 1995;13:661-674.